ESALF - Bristol Myers to pay more than $2 billion to Eisai in a deal for experimental cancer therapy

metamorworks/iStock via Getty Images Bristol-Myers Squibb (BMY) and Eisai (ESALF) have announced a global collaboration to jointly develop and commercialize MORAb-202, an antibody-drug conjugate ((ADC)) currently undergoing studies in Japan and the U.S. for a range of cancers. The two companies will jointly develop and commercialize MORAb-202 in countries such as Japan, China, Europe, and the U.S. Bristol Myers will be solely responsible for the development and commercialization of the experimental therapy in regions outside the collaboration territories while Eisai will be responsible for manufacturing and supply of MORAb-202 globally. As part of the deal, Eisai is entitled to receive more than $2B in total payments from Bristol Myers including $200M for Eisai’s research and development expenses and royalties on sales outside of the collaboration territories. Potential milestone payments for Eisai are estimated at $2.5B. Eisai is currently advancing MORAb-202 in a Phase 1 trial in Japan and Phase 1/2

For further details see:

Bristol Myers to pay more than $2 billion to Eisai in a deal for experimental cancer therapy